Main Symptoms of Tigecycline Toxicity
Tigecycline, an intravenous glycylcycline antibiotic used for complicated infections, can cause toxicity primarily through overdose, prolonged use, or hypersensitivity. Common symptoms include:
- Gastrointestinal effects: Nausea (up to 26% of patients), vomiting (18%), diarrhea (13%), and abdominal pain. These stem from its bacteriostatic mechanism disrupting gut flora and direct mucosal irritation.[1][2]
- Hepatic issues: Elevated liver enzymes (ALT/AST increases in 10-15%), cholestasis, or acute liver injury, especially with high doses exceeding 100 mg/day.[3]
- Pancreatitis: Abdominal pain with elevated amylase/lipase, reported in post-marketing cases linked to cumulative exposure.[4]
These arise because tigecycline inhibits protein synthesis in bacteria but accumulates in human tissues at high levels, with a long half-life (up to 42 hours) prolonging exposure.[1]
Why Nausea and Vomiting Dominate
Tigecycline's poor oral bioavailability and bile excretion lead to high GI concentrations, triggering emesis centers. In clinical trials, 20-30% discontinued due to these; they're dose-dependent and peak within hours of infusion.[2][5]
Serious or Less Common Toxicity Signs
- Hypersensitivity: Rash, anaphylaxis, or Stevens-Johnson syndrome (rare, <1%).[1]
- Hematologic: Thrombocytopenia or anemia from bone marrow suppression.[3]
- Renal: Acute kidney injury in patients with pre-existing impairment, due to proximal tubule accumulation.[4]
- Neurotoxicity: Dizziness or seizures (very rare, tied to overdoses >200 mg).[6]
Overdose cases (e.g., 36 g total dose) show reversible multi-organ effects managed with supportive care like hemodialysis (limited efficacy due to high protein binding).[7]
What Happens in Overdose
Symptoms escalate rapidly: profound nausea/vomiting first, followed by liver enzyme spikes within 24-48 hours. No specific antidote exists; treatment is discontinuation, hydration, and monitoring. Fatalities are rare but linked to superinfections from prolonged use.[1][7]
At-Risk Patients and Prevention
Elderly, obese, or hepatic-impaired patients face higher risk due to reduced clearance. Guidelines cap doses at 100 mg BID; monitor LFTs weekly. Avoid in pregnancy (Category D, fetal bone growth risks).[2][5]
How It Compares to Other Tetracyclines
Unlike doxycycline (milder GI effects), tigecycline's IV-only route and higher tissue penetration amplify toxicity. Minocycline adds vestibular issues absent here.[3]
[1]: FDA Label - Tygacil (tigecycline)
[2]: PubMed - Tigecycline safety review
[3]: Clinical Infectious Diseases - Adverse events
[4]: Drug Safety - Post-marketing pancreatitis
[5]: IDSA Guidelines - Tigecycline use
[6]: ToxNet - Tigecycline overdose
[7]: Clinical Toxicology - Overdose case series